Novavax have published phase 3 trial data showing positive efficacy results for it in the UK

Novavax has published positive data from the UK phase 3 study of its COVID-19 vaccine candidate, showing it to be 89.3% effective in preventing coronavirus in participants.

It will be manufactured in Teesside with 60 million doses already ordered by UK government.